



Federazione
Centri per la diagnosi
della trombosi e la
Sorveglianza delle terapie
Antitrombotiche (**FCSA**)

XXIX Congresso Nazionale FCSA


Bologna 22-23 ottobre 2018

Savoia Hotel Regency

Update sull'uso e consumi degli anticoagulanti in Italia


CIAMPA ANTONIO

Composizione della spesa farmaceutica 2017




- spesa farmaceutica totale 2017, pubblica e privata, pari a 29,8 miliardi di euro
- 75% rimborsato dal SSN
- In media, per ogni cittadino italiano, la spesa ammontava a circa 492 euro
- In media, ogni cittadino ha assunto 1,7 dosi ogni giorno

Prevalenza d'uso e consumo per età e genere




Distribuzione degli utilizzatori nella popolazione di età ≥ 65 anni per numero di sostanze diverse




Oltre il 64% degli utilizzatori anziani ha ricevuto prescrizioni di almeno 5 sostanze e il 21,6% dei soggetti di età pari a o superiore ai 65 anni assume almeno 10 principi attivi diversi


Distribuzione per età dei DOA



Distribuzione in base all'indicazione



DISTRIBUZIONE PER GENERE




Caratteristiche basali dei pazienti trattati con i nuovi anticoagulanti orali

	Apixaban	Edoxaban	Dabigatran	Rivaroxaban	Totale
Pazienti	225.457	47.397	207.252	245.584	725.690

Punteggi
CHA₂DS₂-VASc
Score


Genere




Caratteristiche basali dei pazienti trattati con i nuovi anticoagulanti orali

Comorbidity


HAS-BLED scores




COME E' CRESCIUTO IL MERCATO DEI NOA IN ITALIA E IN EUROPA




Andamento del mercato nel 2014



ANDAMENTO MERCATO NOA 2016 IN ALCUNI PAESI EUROPEI



ANDAMENTO MERCATO NOA DICEMBRE 2017




Andamento degli Anticoagulanti in Italia

(fonte IQVIA ex IMS)

L'utilizzo dei NAO in Italia e nel Mondo è in continua espansione


La quota di Mercato dei NAO in Italia nel mercato degli AC supera ormai il 60%

Si va dal 42% in Trentino A.A. a più del 70% in Basilicata, Campania e Liguria



	DOA	AVK
Costo milioni euro	378,4	12,7
% spesa SSN	1,7	0,1
Spesa <i>procapite</i> in euro	6,25	0,21

MERCATO TAO IN ITALIA AL 01/07/18




Andamento degli Anticoagulanti in Italia

(fonte IQVIA ex IMS)


ABRUZZO

NOAC VS VKA (DOTs)



BASILICATA

NOAC VS VKA (DOTs)




Area del grafico

Andamento degli Anticoagulanti in Italia

(fonte IQVIA ex IMS)


CALABRIA

NOAC VS VKA (DOTs)



CAMPANIA

NOAC VS VKA (DOTs)




Andamento degli Anticoagulanti in Italia

(fonte IQVIA ex IMS)


EMILIA ROMAGNA

FRIULI V.G.

NOAC VS VKA (DOTs)



NOAC VS VKA (DOTs)




Andamento degli Anticoagulanti in Italia

(fonte IQVIA ex IMS)


LAZIO

NOAC VS VKA (DOTs)



LIGURIA

NOAC VS VKA (DOTs)




Andamento degli Anticoagulanti in Italia

(fonte IQVIA ex IMS)


LOMBARDIA

NOAC VS VKA (DOTs)



MARCHE

NOAC VS VKA (DOTs)




Andamento degli Anticoagulanti in Italia

(fonte IQVIA ex IMS)


MOLISE

NOAC VS VKA (DOTs)



PIEMONTE

NOAC VS VKA (DOTs)




Andamento degli Anticoagulanti in Italia

(fonte IQVIA ex IMS)


PUGLIA

NOAC VS VKA (DOTs)



SARDEGNA

NOAC VS VKA (DOTs)




Andamento degli Anticoagulanti in Italia

(fonte IQVIA ex IMS)


SICILIA

NOAC VS VKA (DOTs)



TOSCANA

NOAC VS VKA (DOTs)




Andamento degli Anticoagulanti in Italia

(fonte IQVIA ex IMS)


TRENTINO A.A.

NOAC VS VKA (DOTs)



UMBRIA

NOAC VS VKA (DOTs)




Andamento degli Anticoagulanti in Italia

(fonte IQVIA ex IMS)

VALLE D'AOSTA

NOAC VS VKA (DOTs)



VENETO

NOAC VS VKA (DOTs)

